Last reviewed · How we verify
Camochin (AMODIAQUINE)
Amodiaquine (Camochin) is a marketed antimalarial drug that operates by inhibiting histamine N-methyltransferase, with a key composition patent expiring in 2028. Its mechanism of action provides a distinct therapeutic approach compared to other antimalarials in the same class, such as chloroquine and hydroxychloroquine, which are off-patent and widely available as generics. The primary risk to Amodiaquine's market position is the strong competition from established generics and the upcoming patent expiry of tafenoquine in 2035, which could further erode its market share.
At a glance
| Generic name | AMODIAQUINE |
|---|---|
| Drug class | amodiaquine |
| Target | Heparanase, Histamine N-methyltransferase, Nuclear receptor subfamily 4 group A member 2 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar (PHASE3)
- OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa (PHASE4)
- Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya
- Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects (PHASE1)
- Perennial Malaria Chemoprevention in the Malaria Vaccine Era (PHASE4)
- Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (PHASE4)
- A Study to Find Out if a Combination of 3 Medicines for the Treatment of Malaria Works as Well and is as Safe and Tolerable as Combinations of 2 Medicines (PHASE3)
- A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Camochin CI brief — competitive landscape report
- Camochin updates RSS · CI watch RSS